Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Cholesterol Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy

NCT00260442
View directory record Official record
Conditions
Sarcopenia, Cardiovascular Disease
Interventions
Resistance Training, Sedentary
Behavioral
Lead sponsor
Texas A&M University
Other
Eligibility
50 Years to 69 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

NCT00021463
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

NCT00986986
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Endothelial Dysfunction
Interventions
extended release niacin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

NCT00028301
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Lopinavir/Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Sep 22, 2026, 10:06 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

NCT05331053
View directory record Official record
Conditions
Endometriosis
Interventions
Atorvastatin
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus

NCT00403533
View directory record Official record
Conditions
Hepatitis C
Interventions
20 mg of atorvastatin daily
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2006 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional

Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome

NCT03542240
View directory record Official record
Conditions
Obesity, High Blood Pressure, High Cholesterol, Type2 Diabetes, Heart Diseases
Interventions
Curcumin
Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Compare Effects of a Soluble Fiber on Weight and Blood Cholesterol

NCT00682916
View directory record Official record
Conditions
Obesity
Interventions
Y288
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 22, 2026, 10:06 PM EDT
Terminated No phase listed Observational

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

NCT00260299
View directory record Official record
Conditions
Mevalonic Aciduria, Mevalonate Kinase Deficiency, Immune System Diseases, Periodic Fever Syndromes, Hereditary, Lipid Metabolism, Inborn Errors
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
20
States / cities
Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 22, 2026, 10:06 PM EDT
Recruiting Not applicable Interventional

Multicomponent Intervention Study- Blood Donors With High Cholesterol

NCT05693701
View directory record Official record
Conditions
Lipid Metabolism Disorder
Interventions
Implementation Strategy Bundle, Usual care notification
Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stop Atherosclerosis in Native Diabetics Study

NCT00147251
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes, Carotid Atherosclerosis
Interventions
FDA approved drugs to treat blood pressure and cholesterol
Drug
Lead sponsor
Cynthia West
Other
Eligibility
40 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chinle, Arizona • Phoenix, Arizona • Lawton, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 22, 2026, 10:06 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels and Chinese Red Yeast Rice in the Blood

NCT02142569
View directory record Official record
Conditions
Cholesterol Lowering
Interventions
Sugar Pill, Chinese Red Yeast Rice (CRYR), CRYR + TRF, Tocotrienol-enriched Fraction of Palm Oil (TRF)
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 22, 2026, 10:06 PM EDT
Withdrawn Not applicable Interventional

Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia

NCT03756779
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Dietary intervention
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional

Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease

NCT02646488
View directory record Official record
Conditions
Cardiovascular Disease, High Blood Pressure
Interventions
Million Hearts ABCS 6 Months, Million Hearts ABCS 9 Months, Million Hearts ABCS 12 Months, Million Hearts ABCS 15 Months, Standard Care Regimen 9 Months, Standard Care Regimen 12 Months, Standard Care Regimen 15 Months, Standard Care Regimen 18 Months, Standard Care Regimen 21 Months, Standard Care Regimen 24 Months, Standard Care Regimen 27 Months, Follow Up Post Intervention 21 Months, Follow Up Post Intervention 24 Months, Follow Up Post Intervention 27 Months, Follow Up Post Intervention 30 Months, Follow Up Post Intervention 33 Months
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2019 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease

NCT02622282
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Text Messages, Phone Calls, Handout
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Nutrisystem Meal Provision on Weight

NCT01252303
View directory record Official record
Conditions
Obesity
Interventions
Nutrisystem
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional

Transform Type 2: Examining Meal-Delivery and Education for Diabetes Self-Care

NCT04810026
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Type 2
Interventions
Education, Meal delivery, Lifestyle coaching
Behavioral
Lead sponsor
UnitedHealth Group
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

NCT00813527
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Lapaquistat acetate and fenofibrate, Fenofibrate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
32
States / cities
Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

NCT00004266
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Lisinopril, Nifedipine, Simvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

NCT00143663
View directory record Official record
Conditions
Dyslipidemia
Interventions
Lapaquistat Acetate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
47
States / cities
Northport, Alabama • Mesa, Arizona • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NUYou:mHealth Intervention to Preserve and Promote Ideal Cardiovascular Health

NCT02496728
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Mobile Health Application, Environmental Cues, Social Support, Educational Materials
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
17 Years to 26 Years
Enrollment
302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 19, 2019 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

NCT00129792
View directory record Official record
Conditions
Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions
Dietary supplement for weight loss, Education and counseling for weight loss
Drug · Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

NCT04992065
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 22, 2026, 10:06 PM EDT